VIENNA, Austria, April 05, 2023 (GLOBE NEWSWIRE) -- Proxygen, a leader in the discovery and development of molecular glue degraders, announced today a multi-year research collaboration and license ...
Vienna, Austria, March 31, 2026 (GLOBE NEWSWIRE)-- Vienna, Austria, March 31, 2026 - Proxygen, a biotechnology company pioneering the discovery of molecular glue degraders and next-generation ...
Proxygen Expands Platform Beyond Degradation to Build Next-Generation Induced Proximity Therapeutics
Proxygen announces two lead programs approaching clinical development, p300 and CDK12, addressing multiple cancer types Vienna, Austria, April 28, 2026 – Proxygen, a biotechnology company pioneering ...
The momentum behind Proxygen continues on as the molecular glue degraders development company inked a multi-year research collaboration and license agreement worth up to $2.55 billion with Merck ...
Proxygen has added another big pharma company to its list of partners, with Merck & Co the latest to be snared by its molecular glue degrader technology. Merck – known as MSD outside North America – ...
- New collaboration strengthens Boehringer Ingelheim’s cancer research strategy to develop novel treatment options for patients with lung or gastrointestinal cancers - Proxygen’s unique molecular glue ...
VIENNA--(BUSINESS WIRE)--Proxygen, a leader in the discovery and development of molecular glue degraders, announced today that the company has entered into a strategic multi-year research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results